File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Effects of once-monthly oral ibandronate on serum ctx levels: results of a 3-month randomized trial

TitleEffects of once-monthly oral ibandronate on serum ctx levels: results of a 3-month randomized trial
Authors
Issue Date2006
PublisherSpringer-Verlag
Citation
IOF World Congress on Osteoporosis, Toronto, Canada, 2-6 June 2006. In Osteoporosis International, 2006, v. 17 n. S2, p. S235 Abstract no. P383SU How to Cite?
AbstractAims: Once-monthly oral ibandronate does not maintain stable reduction in bone resorption, suggesting that some persons taking the drug may have little reduction in turnover for at least part of the dosing interval. Because the extent of reduction in turnover is correlated with clinical efficacy of bisphosphonates, this may have important clinical consequences. To explore this question, we examined the proportion of participants who reached specified threshold levels of resorption marker reduction. Methods: Postmenopausal osteoporotic women participated in a 3-month, randomized, double-blind, placebo-controlled clinical trial. Enrolled participants were randomized to receive ibandronate 150 mg or 100 mg or matching placebo every 4 weeks for 3 doses. Serum CTx was measured just prior to each dose, one week after each dose, and weekly for 4 weeks after the final dose. Geometric mean percent change from baseline was calculated, as was the proportion of participants who had marker reductions of at least 40%, 50%, and 60% at each time point after the third dose (Weeks 9–12). Results: At each week after dosing a progressively smaller proportion of women met the defined sCTx reduction thresholds. Fewer than half of women taking 150 mg of ibandronate had sCTx reductions of at least 60% at all 4 weeks after the third dose (Weeks 9–12) and fewer than three-quarters (71.9%) of women had reductions of at least 40% at all four weeks. Conclusions: With once-monthly dosing of oral ibandronate, the proportion of women who attain specified reductions in sCTx declines progressively with time between doses. Because the observed cyclic changes in bone resorption might affect efficacy, the possible clinical implications of intermittent dosing deserve further study.
Persistent Identifierhttp://hdl.handle.net/10722/102021
ISSN
2015 Impact Factor: 3.445
2015 SCImago Journal Rankings: 1.460

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorGeusens, Pen_HK
dc.contributor.authorWalliser, Jen_HK
dc.contributor.authorRovayo, Ren_HK
dc.contributor.authorShivaprakash, Men_HK
dc.contributor.authorVerbruggen, Nen_HK
dc.contributor.authorWehren, LEen_HK
dc.contributor.authorMelton, MEen_HK
dc.date.accessioned2010-09-25T20:13:54Z-
dc.date.available2010-09-25T20:13:54Z-
dc.date.issued2006en_HK
dc.identifier.citationIOF World Congress on Osteoporosis, Toronto, Canada, 2-6 June 2006. In Osteoporosis International, 2006, v. 17 n. S2, p. S235 Abstract no. P383SU-
dc.identifier.issn0937-941X-
dc.identifier.urihttp://hdl.handle.net/10722/102021-
dc.description.abstractAims: Once-monthly oral ibandronate does not maintain stable reduction in bone resorption, suggesting that some persons taking the drug may have little reduction in turnover for at least part of the dosing interval. Because the extent of reduction in turnover is correlated with clinical efficacy of bisphosphonates, this may have important clinical consequences. To explore this question, we examined the proportion of participants who reached specified threshold levels of resorption marker reduction. Methods: Postmenopausal osteoporotic women participated in a 3-month, randomized, double-blind, placebo-controlled clinical trial. Enrolled participants were randomized to receive ibandronate 150 mg or 100 mg or matching placebo every 4 weeks for 3 doses. Serum CTx was measured just prior to each dose, one week after each dose, and weekly for 4 weeks after the final dose. Geometric mean percent change from baseline was calculated, as was the proportion of participants who had marker reductions of at least 40%, 50%, and 60% at each time point after the third dose (Weeks 9–12). Results: At each week after dosing a progressively smaller proportion of women met the defined sCTx reduction thresholds. Fewer than half of women taking 150 mg of ibandronate had sCTx reductions of at least 60% at all 4 weeks after the third dose (Weeks 9–12) and fewer than three-quarters (71.9%) of women had reductions of at least 40% at all four weeks. Conclusions: With once-monthly dosing of oral ibandronate, the proportion of women who attain specified reductions in sCTx declines progressively with time between doses. Because the observed cyclic changes in bone resorption might affect efficacy, the possible clinical implications of intermittent dosing deserve further study.-
dc.languageengen_HK
dc.publisherSpringer-Verlag-
dc.relation.ispartofOsteoporosis Internationalen_HK
dc.titleEffects of once-monthly oral ibandronate on serum ctx levels: results of a 3-month randomized trialen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailKung, AWC: awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00198-006-0095-0-
dc.identifier.hkuros118521en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats